Cards you may also be interested in
Covid-19 Impact and Future Scenario For Medical Ceramics - Research, Future Analysis
The global spread of COVID-19 has led to the complete suspension of elective surgeries, especially in the most affected countries. Some regions witnessed a 70% reduction in the number of patients seeking aesthetic treatments from January 2020 onwards. Moreover, several dental events have been postponed due to the COVID-19 pandemic.  For instance, KRAKDENT 2020, the largest dental show in Poland and an event that attracts over 15,000 visitors worldwide has been rescheduled. The CEO of Straumann Group announced that the COVID-19 outbreak was expected to reduce sales in the Asia Pacific in FY 2020 by at least USD 31 million. Additionally, DENTSPLY Sirona recently predicted that its sales in the Chinese, South Korean, Taiwanese, and Japanese markets would fall by a cumulative USD 60–70 million in FY 2020.   Medical implants are artificial devices that are used to replace damaged or missing biological parts. Implants help deliver medication, monitor body functions, and provide support to organs and tissues in different applications (such as dental, orthopedic, and cardiovascular).   The medical implants market is driven by the growing healthcare needs of the senior population, advancements in medical technologies, and the rising incidence of chronic diseases, such as osteoarthritis, cardiovascular diseases, neuropathic diseases, and congenital disorders, among others.  The significant growth in the geriatric population is expected to result in an increased demand for joint reconstruction, cardiovascular surgeries, and dental replacement procedures and an increase in the prevalence of hearing loss. These factors are, in turn, expected to support the growth of the hearing, orthopedic, and dental implants market.  For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=237425129 Medical ceramics are key components in the manufacturing of various implantable devices, such as orthopedic implants (artificial hips, knee, shoulder, wrists, fracture fixation, and bone grafts), cardiovascular implants (heart valves, pacemakers, catheters, grafts, and stents), dental implants (enamels, fillings, prosthetics, and orthodontics), and hearing implants (cochlear implants).  Considering the growing demand for implantable devices in different segments (such as cardiovascular, dental, and orthopedics), the uptake of medical ceramics is expected to increase in the coming years.  These products have to be implanted inside the human body; they need to be biocompatible and comply with the ISO biocompatibility testing standards. However, it is difficult to anticipate the biocompatibility till the later stages of clinical trials, making companies and investors apprehensive of investing in this market.  Also, regulatory procedures are complicated, restrictive, and depend on the composition of ceramics and their future applications, making the approval process for medical ceramic products cumbersome, expensive, and time-consuming. These factors are expected to hinder the growth of the medical ceramics market to a certain extent.  The World Economic Forum estimates these emerging economies to account for around one-third of the global healthcare expenditure by 2020. The rising geriatric population in these countries will lead to increased demand for medical facilities and devices, which is likely to propel the growth of the medical ceramics market. Moreover, growth in these markets can primarily be attributed to the low prices of dental treatments in these countries compared to developed economies and their infrastructural development.   Additionally, medical device manufacturers are also setting up their facilities in the Asia Pacific, the Middle East, and Latin America. In recent years, key players such as Baxter International, Becton Dickinson, BIOTRONIK, Hoya Surgical Optics, Life Technologies, Medtronic, Siemens Medical Instruments, and AB SCIEX have set up their manufacturing and RD facilities in Singapore.  The lack of a skilled workforce and proper techniques to repair further highlight the issue of reparability. Medical ceramics have a long lifespan but are not recyclable. Due to the long lifespan and various mechanical and optical properties of medical ceramics, the different composites used in various end-use applications face recyclability and reparability. This is one of the major challenges hampering the growth of the medical ceramics market.  The medical ceramics market in Asia Pacific, particularly in China, Japan, and India, is expected to witness high growth in the coming five years. The medical ceramics market in the APAC is estimated to grow rapidly during the forecast period, considering the development of the region's healthcare sector. The major consumers of medical ceramics in the APAC are China, South Korea, and Japan.
Cell Counting Market - Trends, Growth and Future Analysis
The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.  The medical application segment will grow at the highest CAGR in the cell counting market. Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.  The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical RD expenditure, and commercial expansion of various pharmaceutical companies.  For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728 The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.  The major companies in the cell counting market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Bio-Rad Laboratories (US). 
Cleanroom Technology Market to Witness Impressive Growth
The increasing demand in developing economies and the growing focus on energy-efficient cleanrooms are expected to offer significant opportunities for market growth in the coming years. However, the high operational cost associated with the cleanrooms is expected to restrain market growth to a certain extent.  The global health crisis triggered by the COVID-19 pandemic has made it imperative that the pharmaceutical industry moves at a rapid pace alongside researchers, regulators, and contract research companies to develop a diagnosis, treatment, and vaccines. Cleanroom technologies and services play an important role in this scenario to ensure that quality, safety, and efficacy are being maintained.  In the current scenario, the healthcare industry is witnessing an unparalleled demand for diagnostic tests, personal protective equipment (PPE), medical ventilators, and other critical medical supplies. Facing the potentiality of a high risk of infection, healthcare professionals (HCPs) are also facing significant challenges in providing specific and effective care (often remotely).  In Hospital systems are becoming overwhelmed with the rapidly increasing number of COVID-19 patients, which is weighing heavily on the pharmaceutical industry. With the increasing demand for certified products, various quality certifications such as ISO checks and National Safety and Quality Health Standards (NSQHS) have been made mandatory for ensuring that the standards for manufacturing processes and products are being upheld. The quality certifications require products to be processed in a cleanroom environment to ensure minimum possible contamination.   Also, the price per square foot is not the same for ISO 6 and ISO 8 cleanrooms. This is because the amount of air supplied is different in both classes of cleanrooms. The air is 100 times cleaner in an ISO 6 cleanroom than in an ISO 8 cleanroom, thereby doubling the air conditioning capacity of the HVAC systems.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263122482 Cleanrooms are mostly designed according to customer requirements based on product specifications and customer-specific design requirements. However, there are no specific guidelines for cleanroom designs for different application areas or product types. This leads to several challenges for cleanroom manufacturers, as they need to follow different designs every time.  The consumables segment accounted for the larger market share in 2019. The high and growing number of pharmaceutical, biotech, and medical device companies facilitating the use of disposable protective clothing has resulted in the increased adoption of the consumables in the cleanroom technologies market. Also, the large number of RD activities in the healthcare industry is resulting in a stable demand for cleanroom consumables among end-users.   The hardwall cleanrooms segment is expected to witness the highest growth during the forecast period. This is mainly due to the higher demand for hardwall cleanrooms, as they are more design-flexible than standard and softwall cleanrooms, quick and easy to install, freestanding for easy portability, and easy to expand or reconfigure.   This is due to its favorable government regulations, increasing healthcare expenditure, and the growing base of pharma companies in the country, all of which are driving adoption of cleanroom solutions in the Asia Pacific. 
Real World Evidence Are Used To Monitor The Post Market Safety and Adverse Events of Drugs
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be very helpful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while helping to organize and evaluate clinical data for regulatory submissions. The uncertainty brought on by the COVID-19 pandemic has dramatically shifted how and when patients decide to seek medical care. In addition, shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes.   RWE is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak, according to the latest poll on GlobalData’s Pharmaceutical Technology website. In this poll, which was completed by 935 of its readers in April 2021, more than one-third of the respondents indicated that RWE would have the greatest impact on the management of COVID-19.  Even though emerging technologies, such as telemedicine, have existed for decades, most of healthcare systems rely heavily on in-person interactions between patients and clinicians. Nevertheless, the current requirement for social distancing measures is swiftly pushing the primary care provision toward remote care. Telemedicine and virtual care may also prompt a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 The utilization of RWE in infectious disease control is not a new concept. During the Ebola outbreak in 2014, forecasters successfully used Global Epidemic and Mobility (GLEaM) simulations that combined real-world data on populations and their mobility with rigorous stochastic models of disease transmission to predict the global spread of the disease.  In countries with strict data privacy laws, the implications of contact-tracing apps on individual privacy are considered a major associated concern. While cryptographers are currently working on improving tracing apps to address the issue, tracking apps can only be effective when they are used by a significant proportion of the population. Therefore, it is critical that the functionality and safety of these applications are considered acceptable by the majority of the population.  Through the analysis of the data generated from various networks, healthcare organizations can benefit from sensible information, resulting in real-time disease monitoring and control. However, as the use of technology as a means to produce more and more data to drive insights and foresight increases, the ability to automate and analyze that data becomes a necessity. Accelerated digitalization in the healthcare space has revealed gaps in infrastructure, workforce, and digital education that ultimately need to be bridged.   Real World Evidence Solutions Market Dynamics Without intelligent analytics, RWE alone will not be able to produce meaningful and actionable results. Previously, the healthcare industry did not have the ability to gather RWE at the speed and scale needed to address urgent public health crises. However, this scenario has changed due to the pandemic. Advances in analytics and access to broad and diverse real-world data sets have made it possible to rapidly analyze data as it is captured to better understand how pandemics like COVID-19 are unfolding.  The pre-approved use of RWE in efficacy decisions is being carried out currently, and there is potential for it to be used more broadly, such as in oncology, rare diseases, and pediatric conditions when randomized controlled clinical trials are impossible or unethical to conduct. In parallel, legislators are recognizing the value of RWE. In the US, the 21st Century Cures Act, passed in December 2016, has established public-private partnerships to collect data and improve the understanding of diseases.